Welcome to our dedicated page for QUEST DIAGNOSTICS SEC filings (Ticker: DGX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Quest Diagnostics Incorporated filings document a public diagnostic information services company with common stock listed on the New York Stock Exchange under DGX. The company’s 8-K reports disclose operating results, guidance updates, investor presentation materials, dividends, share repurchase authorizations, senior unsecured debt issuance and other material agreements tied to its capital structure.
Proxy filings describe annual meeting proposals, director elections, board committee assignments, governance practices, executive compensation and the company’s strategy for diagnostic testing insights, healthcare-provider relationships, data assets, automation and artificial intelligence. The filing record also documents shareholder voting matters and formal changes in board composition.
Quest Diagnostics senior vice president and chief commercial officer Mark E. Delaney reported a small, automatic share disposition related to taxes. On the transaction date, 188 shares of common stock were withheld at a price of $204.86 per share to satisfy tax obligations from vesting restricted share units. After this tax-withholding event, Delaney directly owned 8,508 Quest Diagnostics common shares.
Quest Diagnostics senior executive reports small tax-related share disposition. Michael J. Deppe, SVP, Corporate Controller and Chief Accounting Officer of Quest Diagnostics, had 88 shares of common stock withheld at $204.86 per share on a Form 4 event dated March 2, 2026 to satisfy tax obligations from previously vested restricted share units, rather than an open-market sale. After this transaction, he directly held 34,473 shares of Quest Diagnostics common stock. The filing also notes indirect ownership of 706 shares through the company’s 401(k) Profit Sharing Plan, with balances based on plan administrator data.
Catherine T. Doherty reported sales of Common Stock under a Form 144 filing. The filing lists sales of $5,393,815.32 for 26,165 shares on 02/13/2026 and $293,521.39 for 1,433 shares on 02/19/2026.
The filing also shows 632 shares tied to restricted stock vesting dated 02/23/2026, identified as securities to be sold. The transactions are reported on a Form 144 related to Common shares.
DGX Form 144 notice reports an intended sale of common stock by a reporting person and prior open‑market sales. The notice lists 526 shares tied to restricted stock vesting on 02/23/2026 and prior sales of 1,111 common shares on 02/19/2026 that generated $227,566.13. The broker listed is Fidelity Brokerage Services LLC and the filing shows 03/03/2026 on the NYSE.
Form 144 notice: proposed dispositions of common stock by an insider and a restricted-stock vesting. The filing lists a restricted stock vesting of 410 shares on 02/23/2026 recorded as compensation. It also shows proposed sales by Thomas P. Plewman of 5,662 shares on 02/10/2026 and 958 shares on 02/19/2026 with corresponding aggregate dollar amounts disclosed in the excerpt.
DGX filed a Form 144 reporting a proposed sale of 10,000 common shares through Fidelity Brokerage Services LLC. The filing lists an aggregate value of $2,125,200.00, shows the figure 109,866,320, and is dated 03/02/2026 with NYSE noted.
Quest Diagnostics describes how it generates growth and improves efficiency across its global diagnostics business. The company generated net revenues of $11.0 billion in 2025 and now serves roughly half of U.S. adults over three years, with strong physician and hospital penetration.
Advanced Diagnostics™ tests in oncology, cardiometabolic and other specialties produced over $1 billion of revenue with double-digit growth, underscoring a shift toward higher‑value testing. Quest expanded through acquisitions such as LifeLabs in Canada and Spectra Laboratories assets, and a 51%/49% joint venture with Corewell Health in Michigan.
Management highlights ongoing cost and quality programs, including the Invigorate savings initiative, a multi‑year Project Nova overhaul of order‑to‑cash systems, and broader use of automation and AI, including a 2025 collaboration with Google Cloud. The company also raised its quarterly dividend about 7.5% to $0.86 per share and reports a workforce of nearly 57,000 employees.
Quest Diagnostics senior vice president Patrick Plewman reported a mix of stock transactions and equity awards. On February 19, 2026, he completed an open‑market sale of 958 shares of common stock, leaving him with 15,838 shares held directly.
On February 18, 2026, he received a grant of 9,009 non-qualified stock options, which vest in three equal annual installments starting on the first anniversary of the grant date. He was also awarded 1,952 restricted stock units.
That same day, a total of 537 shares of common stock (244 shares at one price and 293 shares at another) were surrendered to the issuer solely to cover tax withholding obligations from vesting restricted stock units. The footnotes state the 958‑share sale was executed under a pre-arranged Rule 10b5‑1 trading plan adopted by Plewman.
Quest Diagnostics Executive Vice President and CFO Sam Sam reported several equity-related transactions. On February 18, 2026, he received a grant of 18,303 non-qualified stock options with an exercise right to buy shares, which vest in three equal annual installments beginning on the first anniversary of the grant date. He also acquired 3,965 shares of common stock as an award of restricted stock units and disposed of 855 and 1,010 shares of common stock solely to cover tax withholding obligations arising from the vesting of restricted stock units, at prices of $210.01 and $206.99 per share. In addition, on January 28, 2026, he acquired 69 shares of common stock through a dividend reinvestment plan at $183.514 per share. Following these transactions, his directly held common stock position was reported as 27,841 shares, and he directly held 18,303 options.
Quest Diagnostics SVP & General Counsel Michael E. Prevoznik reported a mix of stock transactions. On February 19, 2026, he sold 1,111 shares of common stock in an open-market transaction at $204.83 per share, executed under a Rule 10b5-1 sales plan.
On February 18, 2026, he received a grant of 9,289 non-qualified stock options with an exercise right to buy shares, which vest in three equal annual installments beginning on the first anniversary of the grant. He also acquired 2,013 shares of common stock as an award of restricted stock units, while 301 shares at $210.01 and 347 shares at $206.99 of common stock were surrendered to cover tax withholding from vesting. In addition, 5,738 shares are held indirectly through company 401(k) and deferred compensation plans.